Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema

Acta Ophthalmologica

Volumn 86, Issue 7, 2008, Pages 800-805

  Fang, Xiaoyun ^a   Sakaguchi, Hirokazu ^a   Gomi, Fumi ^a   Oshima, Yusuke ^a   Sawa, Miki ^a   Tsujikawa, Motokazu ^a   Ikuno, Yasushi ^a   Kamei, Motohiro ^a   Kusaka, Shunji ^a   Tano, Yasuo ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Bevacizumab; Diabetic retinopathy; Macular oedema; Optical coherence tomography

Indexed keywords

BEVACIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CENTRAL RETINA THICKNESS; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAOCULAR PRESSURE; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA; SLIT LAMP; THICKNESS; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; FEMALE; HUMANS; INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 55449084692     PISSN: 1755375X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2008.01254.x     Document Type: Article

References (27)

1. Aiello LP, Avery RL, Arrigg PG et al. (1994): Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487.
2. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L & Maia M (2007): Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular oedema: Results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114: 743-750.
3. Avery RL, Pearlman J, Pieramici DJ et al. (2006): Intravitreal bevacizumab (Avastin) for the treatment of proliferative diabetic retinopathy. Ophthalmology 113: 1695-1705.
4. Bakri SJ, Snyder MR, Reid JM, Pulido JS & Singh RJ (2007): Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114: 855-859.
5. Chin HS, Park T, Moon YS & On JH (2005): Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and non-vitrectomized eyes. Retina 25: 556-560.
6. Chun DW, Heier JS, Topping TM, Duker JS & Bankert JM (2006): A pilot study of multiple intravitreal injections of ranibizumab in patients with centre-involving clinically significant diabetic macular oedema. Ophthalmology 113: 1706-1712.
7. Cunningham ET Jr, Adamis AP, Altaweel AP et al. (2005): Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular oedema. Ophthalmology 112: 1747-1757.
8. Diabetic Retinopathy Clinical Research Network (2007): A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular oedema. Ophthalmology 114: 1860-1867.
9. Early Treatment Diabetic Retinopathy Study Research Group (1985): Photocoagulation for diabetic macular oedema. ETDRS Report No. 1. Arch Ophthalmol 103: 1796-1806.
10. Funatsu H, Yamashita H, Nakamura S, Mimura T, Eguchi S, Nomal H, Hori S (2006): Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular oedema. Ophthalmology 113: 294-301.
11. Fung AE, Rosenfeld PJ & Reichel E (2006): The International Intravitreal Bevacizumab Safety Survey: Using the Internet to assess drug safety worldwide. Br J Ophthalmol 90: 1344-1349.
12. Gomi F, Nishida K, Oshima Y et al. (2007): Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone. Am J Ophthalmol 143: 507-510.
13. Haritoglou C, Kook D, Neubauer A et al. (2006): Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular oedema. Retina 26: 999-1005.
14. Klein R, Klein BE, Moss SE & Cruickshanks KJ (1995): The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The longterm incidence of macular oedema. Ophthalmology 102: 7-16.
15. Lee CS & Koh HJ (2008): Multiple retinal haemorrhages in diabetic retinopathy after adjunctive intravitreal bevacizumab (Avastin ®) with pars plana vitrectomy. Acta Ophthalmol (in press).
16. Melo GB, Farah ME & Aggio FB (2007): Intravitreal injection of bevacizumab for cystoid macular oedema in retinitis pigmentosa. Acta Ophthalmol Scand 85: 461-463.
17. Minnella AM, Savastano CM, Ziccardi L, Scupola A, Sasso P, Falsini B & Balestrazzi E (2008): Intravitreal bevacizumab (Avastin ®) in proliferative diabetic retinopathy. Acta Ophthalmol (in press).
18. Nguyen QD, Tatlipinar S, Shah SM et al. (2006): Vascular endothelial growth factor is a critical stimulus for diabetic macular oedema. Am J Ophthalmol 142: 961-969.
19. Oshima Y, Sakaguchi H, Gomi F & Tano Y (2006): Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 142: 155-158.
20. Parolini B, Panozzo G, Gusson E, Pinackatt S & Bertoldo G (2004): Diode laser, vitrectomy and intravitreal triamcinolone. A comparative study for the treatment of diffuse non-tractional diabetic macular oedema. Semin Ophthalmol 19: 1-12.
21. Pealson PA, Hainsworth DP & Ashton P (1993): Clearance and distribution of ciprofloxacin after intravitreal injection. Retina 13: 326-330.
22. Sakaguchi H, Ikuno Y, Gomi F et al. (2007): Intravitreal injection of bevacizumab for choroidal neovascularization caused by pathological myopia. Br J Ophthalmol 91: 161-165.
23. Shima C, Sakaguchi H, Gomi F et al. (2008): Complications in patients after intravitreal injections of bevacizumab. Acta Ophthalmol 86: 372-376.
24. Spandau UH, Ihloff AK & Jonas JB (2006): Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 84: 555-556.
25. Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU & Jorge R (2008): Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 86: 385-389.
26. Yanyali A, Aytug B, Horozoglu F & Nohutcu AF (2007): Bevacizumab (Avastin) for diabetic macular oedema in previously vitrectomized eyes. Am J Ophthalmol 144: 124-126.
27. Zimmet P, Alberti KG & Shaw J (2001): Global and societal implications of the diabetes epidemic. Nature 414: 782-787.